Enterprise Value
253.6M
Cash
157.9M
Avg Qtr Burn
-49.52M
Short % of Float
8.81%
Insider Ownership
7.45%
Institutional Own.
60.96%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Botensilimab (AGEN1181) w/ Balstilimab (AGEN2034) Details Colorectal cancer , Cancer | BLA Submission | |
Botensilimab (AGEN1181) (anti-CLTA-4) Details Cancer, Endometrial cancer, Colorectal cancer , Pancreatic cancer, Melanoma | Phase 2 Data readout | |
AGEN1777 (BMS-986442) (TIGIT)+ nivolumab and/or chemotherapies Details Solid tumor/s, Non-small cell lung carcinoma, Cancer, Lung cancer | Phase 2 Update | |
Botensilimab (AGEN1181) + balstilimab Details Cancer, Sarcoma | Phase 1b Data readout | |
Botensilimab (AGEN1181) Details Cancer, Non-small cell lung carcinoma | Phase 1b Data readout | |
AGEN2373 w/ Botensilimab (AGEN1181) Details Solid tumor/s, Cancer, Melanoma | Phase 1b Update | |
Botensilimab (AGEN1181) w/ Balstilimab (AGEN2034) Details Cancer, Ovarian cancer | Phase 1b Update | |
AGEN1571 w/ Botensilimab (AGEN1181) & Balstilimab (AGEN2034) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
AGEN1423 (anti-CD73-TGFβ-trap bifunctional antibody) + balstilimab (anti-PD-1) Details Pancreatic cancer, Cancer | Failed Discontinued | |
Balstilimab (anti- PD-1) + Zalifrelimab (anti-CTLA-4) Details Cancer, Cervical cancer | Failed Discontinued | |
Balstilimab (AGEN2034) Details Cancer, Cervical cancer | Failed Discontinued |